Developing a Batch Isolation Procedure and Running It in an Automated Semicontinuous Unit: AWL CFD25 Case Study.

A key challenge during the transition from laboratory/small batch to continuous manufacturing is the development of a process strategy that can easily be adopted for a larger batch/continuous process. Industrial practice is to develop the isolation strategy for a new drug/process in batch using the design of experiment (DoE) approach to determine the best isolation conditions and then transfer the isolation parameters selected to a large batch equipment/continuous isolation process. This stage requires a series of extra investigations to evaluate the effect of different equipment geometry or even the adaptation of the parameters selected to a different isolation mechanism (e.

Effect of encapsulating a pseudo-decapeptide containing arginine on PLGA: a solid-state NMR study.

The effects of incorporating an amorphous decapeptide in PLGA on the cooperative and local motions of the polymer chains have been evaluated. Whereas assessment of the bulk properties is used traditionally for studies of host-guest interactions, there are only rare examples where molecular-level understanding of such amorphous host-guest systems has been sought. Moreover, addressing the mechanism of interactions and stabilisation of a drug in a polymeric network is a key factor for the achievement of reproducibility of the formulations and ultimately the preparation of composites able to deliver drugs with consistency.

Effect of encapsulating arginine containing molecules on PLGA: a solid-state NMR study.

Design of polymer-drug composites based on the lactide/glycolic acid often rely on the chemical complementarity between the polymer and functional groups in a pharmaceutical guest. We previously characterised decapeptide (AZD)/poly(D,L-lactide-co-glycolide) (PLGA) film formulations aiming at localising the interacting groups responsible for the changes in the bulk properties of the polymer matrix and understanding the mechanism of stabilisation of the drug into the polymer matrix. The results suggested interactions to occur between the arginine residue in the peptide and the carbonyl end group of the polymer chains.